India Disrupts Global Weight-Loss Market with Low-Cost GLP-1 Generics
India's pharmaceutical sector has begun a massive rollout of affordable, generic versions of high-demand weight-loss medications, targeting both domestic and international markets. This influx of low-cost GLP-1 agonists is expected to democratize access to obesity treatments, significantly impacting global retail pharmacy chains and e-commerce health platforms.